Edwards Lifesciences stock is coming off a 21.6% gain over the past three years, while the latest valuation work suggests it may no longer be an obvious bargain, with the Discounted Cash Flow (DCF) estimate sitting close to the current share price and earnings multiples screening as rich.

• Edwards Lifesciences has returned 21.6% over three years, which puts more pressure on today’s valuation to be supported by future cash flows.
• Expectations for ongoing demand in structural heart therapies can support the intrinsic value, although any setback in growth or pricing power may weigh heavily on what investors are willing to pay.
• The company passes 0 of 6 valuation checks, which suggests Edwards Lifesciences does not screen as a clear bargain on Simply Wall St’s broader tests here.

The stock’s next move may depend on whether that three year share price gain is already fully reflecting Edwards Lifesciences’ intrinsic value or still leaves some room above what the current valuation frameworks imply.

Where Does Edwards Lifesciences Sit on Cash Flow?

The Discounted Cash Flow (DCF) model estimates what Edwards Lifesciences is worth based on the cash it can generate for shareholders. For the latest twelve months, the company produced around $1.40b in free cash flow, and the model assumes that these cash flows continue to grow rather than shrink.

Based on these cash flow projections, the DCF points to an intrinsic value of about $92 per share, which is very close to the current share price and implies the stock is roughly 0.6% overvalued. This small gap suggests the market is largely in line with what the cash flow outlook for Edwards Lifesciences currently supports, without a big margin on either side.

Overall, the Discounted Cash Flow analysis indicates that Edwards Lifesciences stock appears to be trading close to its estimated fair value at today’s price.

Edwards Lifesciences is fairly valued according to our Discounted Cash Flow (DCF), but this can change at a moment's notice. Track the value in your watchlist or portfolio and be alerted on when to act.

Has Edwards Lifesciences Run Too Far on Earnings?

The P/E ratio is a useful cross check for Edwards Lifesciences because earnings remain a key reference point for many investors in the medical equipment sector.

Right now, Edwards Lifesciences trades on a P/E of about 54.3x. That is almost double the Medical Equipment industry average of 28.0x and also well above the broader peer average of 28.1x. A more tailored benchmark that factors in the company’s size, margins and risk profile points to a fair P/E of around 34.7x, which still sits well below where the stock currently trades.

This gap means the share price already embeds a rich earnings valuation compared with both industry norms and what the fair ratio model suggests. For investors, the key question is whether the company’s future results can support paying such a premium multiple over time.

On the P/E multiple, Edwards Lifesciences stock currently appears expensive compared with both peers and its modelled fair ratio.

The Edwards Lifesciences Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the Edwards Lifesciences valuation puzzle leaves off. They spell out which future paths for growth, margins and earnings would justify a stock price meaningfully above or below today’s level, and they sit on the company’s Community page. Each narrative links its number to a clear view on how Edwards Lifesciences' growth, profitability and risk profile might evolve, which you can revisit as new information arrives.

You can add your own number driven Narrative on Edwards Lifesciences' growth, margins and execution, and be one of the first voices in the Simply Wall St community to set out a clear case and watch how it holds up as new results arrive.

Do you think there's more to the story for Edwards Lifesciences? Head over to our Community to see what others are saying!

The Bottom Line

For Edwards Lifesciences, the Discounted Cash Flow (DCF) work points to an intrinsic value very close to the current share price, so the stock no longer screens as obviously cheap. At the same time, the market multiple view flags Edwards Lifesciences as overvalued on earnings compared with both peers and a tailored fair P/E. Broader valuation checks are weak, which reinforces that message rather than offsetting it. The key question from here is whether the company can deliver enough cash flow and earnings power to keep justifying a premium multiple without much valuation cushion.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.